Lymphatic filariasis is a parasitic disease caused by microscopic, thread-like worms. The adult worms only live in the human lymph system. The lymph system maintains the body's fluid balance and fights infections. Lymphatic filariasis is spread from person to person by mosquitoes.
People with the disease can suffer from lymphedema and elephantiasis and in men, swelling of the scrotum, called hydrocele. Lymphatic filariasis is a leading cause of permanent disability worldwide. Communities frequently shun and reject women and men disfigured by the disease. Affected people frequently are unable to work because of their disability, and this harms their families and their communities.
A double-blind, randomized, placebo-controlled clinical trial has recently demonstrated that Ivermectin, an anti-parasitic drug, can reduce in-hospital mortality rate of COVID-19 patients.
Brazilian researchers have managed to decipher the structure of a protein found in parasites that cause neglected tropical diseases, paving the way to the development of novel medications.
Global campaigns to eliminate two tropical parasitic worm infections have been hindered by a lack of good diagnostic tools.
The discovery of new drugs is vital to achieving the eradication of neglected tropical diseases (NTDs) in Africa and around the world.
The World Health Organization (WHO) and Sanofi – one of the world's leading pharmaceutical companies – have signed a new agreement for donations of medicines to sustain specific efforts to eliminate neglected tropical diseases (NTDs).
Illustrations by a local artist in Nigeria are helping health workers and policy makers understand what it's really like to live with a neglected tropical disease (NTD).
In 2019, 538.1 million people were treated for lymphatic filariasis (LF) in 38 countries that implemented mass drug administration (MDA) of populations at risk of the disease, as recommended by the World Health Organization (WHO).
For years, many scientists and medical professionals likely misunderstood how a commonly prescribed medication for elephantiasis battled the disease, but a new study sets the record straight.
Scientists have revealed a way to eradicate parasitic worms by stopping them from using alternative metabolism pathways provided by bacteria that live within them, according to new findings published today in eLife.
Researchers uncovered in a new study how schistosomes, parasitic flatworms that infect more than 200 million people in the tropics, trick the host's immune system and continue producing eggs for decades.
Using innovative RNA sequencing techniques, researchers at the University of Maryland School of Medicine Institute for Genome Sciences identified a promising novel treatment for lymphatic filariasis, a disabling parasitic disease that is difficult to treat.
Treatment with two common FDA-approved gout medications have been found to cause rapid death to the parasites that cause elephantiasis.
The Global Program to Eliminate Lymphatic Filariasis delivers mass drug administration to 500 million people each year, and adverse events are common following treatment. Now, researchers have reported in PLOS Neglected Tropical Diseases that certain changes in gene expression are associated with these adverse events.
Malaysia is facing many challenges caused by various parasitic pathogens. The lack of awareness among disadvantaged populations such as the Orang Asli community and the dependency on foreign workers has led to an influx of immigrants to Malaysia from countries endemic with various parasitic diseases.
Researchers from LSTM and the University of Liverpool have successfully optimized a hit from a whole cell screening of a 10000-compound library to deliver the first novel fully synthetic and rationally designed anti-Wolbachia drug, AWZ1066S, which could potentially be used to treat onchocerciasis and lymphatic filariasis.
Researchers from Case Western Reserve University School of Medicine have shown that a single "cocktail" of three pill-based anti-parasite medications is significantly more effective at killing microscopic larval worms in people diagnosed with lymphatic filariasis, commonly known as elephantiasis, than other standard two-drug combinations previously used in the global effort to eliminate this infectious disease.
An LSTM led partnership has been awarded nearly £1.5 million from the Medical Research Council for the pre-clinical development of a candidate drug to treat onchocerciasis and lymphatic filariasis, by targeting the bacterial symbiont Wolbachia.
To ensure elimination of the Wuchereria bancrofti, a parasitic roundworm that causes lymphatic filariasis, public health workers must follow up mass drug administration with careful monitoring for recurrence.
River blindness and elephantiasis are debilitating diseases caused by parasitic worms that infect as many as 150 million people worldwide.
World Health Organization and Uniting to Combat NTDs collaborate to tackle the five most common Neglected tropical diseases; onchocerciasis, trachoma, schistosomiasis, lymphatic filariasis and helminthic infections.